A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of Intravenous and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis on Stable Methotrexate.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of Intravenous and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis on Stable Methotrexate.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Olokizumab (Primary) ; Olokizumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 29 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top